BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21656181)

  • 1. In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment.
    Rudolph G; Gotthardt DN; Kloeters-Plachky P; Kulaksiz H; Schirmacher P; Stiehl A
    Dig Dis Sci; 2011 Dec; 56(12):3624-30. PubMed ID: 21656181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.
    Eaton JE; Silveira MG; Pardi DS; Sinakos E; Kowdley KV; Luketic VA; Harrison ME; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Lindor KD
    Am J Gastroenterol; 2011 Sep; 106(9):1638-45. PubMed ID: 21556038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.
    Lindström L; Boberg KM; Wikman O; Friis-Liby I; Hultcrantz R; Prytz H; Sandberg-Gertzén H; Sangfelt P; Rydning A; Folvik G; Gangsøy-Kristiansen M; Danielsson A; Bergquist A
    Aliment Pharmacol Ther; 2012 Feb; 35(4):451-7. PubMed ID: 22221173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature.
    Wang R; Leong RW
    World J Gastroenterol; 2014 Jul; 20(27):8783-9. PubMed ID: 25083052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.
    Färkkilä M; Karvonen AL; Nurmi H; Nuutinen H; Taavitsainen M; Pikkarainen P; Kärkkäinen P
    Hepatology; 2004 Dec; 40(6):1379-86. PubMed ID: 15565569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.
    Imam MH; Sinakos E; Gossard AA; Kowdley KV; Luketic VA; Edwyn Harrison M; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Keach J; DeCook AC; Enders F; Lindor KD
    Aliment Pharmacol Ther; 2011 Nov; 34(10):1185-92. PubMed ID: 21957881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study.
    Sjöqvist U; Tribukait B; Ost A; Einarsson C; Oxelmark L; Löfberg R
    Anticancer Res; 2004; 24(5B):3121-7. PubMed ID: 15510599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
    Lindor KD; Kowdley KV; Luketic VA; Harrison ME; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Keach J; Mooney J; Sargeant C; Braaten J; Bernard T; King D; Miceli E; Schmoll J; Hoskin T; Thapa P; Enders F
    Hepatology; 2009 Sep; 50(3):808-14. PubMed ID: 19585548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis.
    Charatcharoenwitthaya P; Angulo P; Enders FB; Lindor KD
    Hepatology; 2008 Jan; 47(1):133-42. PubMed ID: 17992695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary sclerosing cholangitis and bile acids.
    Chazouillères O
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S21-5. PubMed ID: 23141889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.
    Sinakos E; Marschall HU; Kowdley KV; Befeler A; Keach J; Lindor K
    Hepatology; 2010 Jul; 52(1):197-203. PubMed ID: 20564380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study.
    Jørgensen KK; Lindström L; Cvancarova M; Castedal M; Friman S; Schrumpf E; Foss A; Isoniemi H; Nordin A; Holte K; Rasmussen A; Bergquist A; Vatn MH; Boberg KM
    Scand J Gastroenterol; 2012 Sep; 47(8-9):1021-9. PubMed ID: 22577871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children.
    Gilger MA; Gann ME; Opekun AR; Gleason WA
    J Pediatr Gastroenterol Nutr; 2000 Aug; 31(2):136-41. PubMed ID: 10941964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study.
    Garioud A; Seksik P; Chrétien Y; Corphechot C; Poupon R; Poupon RE; Chazouillères O
    Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):842-7. PubMed ID: 19779305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary sclerosing cholangitis associated with inflammatory bowel disease: an update.
    Rossi RE; Conte D; Massironi S
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):123-31. PubMed ID: 26636407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary sclerosing cholangitis.
    Stiehl A; Benz C; Sauer P
    Can J Gastroenterol; 2000 Apr; 14(4):311-5. PubMed ID: 10799084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
    Mitchell SA; Bansi DS; Hunt N; Von Bergmann K; Fleming KA; Chapman RW
    Gastroenterology; 2001 Oct; 121(4):900-7. PubMed ID: 11606503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.
    Pardi DS; Loftus EV; Kremers WK; Keach J; Lindor KD
    Gastroenterology; 2003 Apr; 124(4):889-93. PubMed ID: 12671884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis.
    Singh S; Khanna S; Pardi DS; Loftus EV; Talwalkar JA
    Inflamm Bowel Dis; 2013 Jul; 19(8):1631-8. PubMed ID: 23665966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
    Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
    Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.